Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in breast cancer post-treatment follow-up: a study protocol for a phase II randomised controlled trial (the EMINENT trial).
Chan RJ, Emery J, Cuff K, Teleni L, Simonsen C, Turner J, Janda M, Mckavanagh D, Jones L, McKinnell E, Gosper M, Ryan J, Joseph R, Crowe B, Harvey J, Ryan M, Carrington C, Nund R, Crichton M, McPhail S. Chan RJ, et al. Trials. 2020 Oct 15;21(1):855. doi: 10.1186/s13063-020-04740-1. Trials. 2020. PMID: 33059741 Free PMC article.
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol.
Pryor D, Bressel M, Lawrentschuk N, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Neha N, Shaw M, Chander S, Neeson P, Moon D, Cuff K, Wood S, Murphy DG, Sandhu S, Loi S, Siva S. Pryor D, et al. Contemp Clin Trials Commun. 2021 Jan 6;21:100703. doi: 10.1016/j.conctc.2021.100703. eCollection 2021 Mar. Contemp Clin Trials Commun. 2021. PMID: 33490707 Free PMC article.
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.
Chew HY, De Lima PO, Gonzalez Cruz JL, Banushi B, Echejoh G, Hu L, Joseph SR, Lum B, Rae J, O'Donnell JS, Merida de Long L, Okano S, King B, Barry R, Moi D, Mazzieri R, Thomas R, Souza-Fonseca-Guimaraes F, Foote M, McCluskey A, Robinson PJ, Frazer IH, Saunders NA, Parton RG, Dolcetti R, Cuff K, Martin JH, Panizza B, Walpole E, Wells JW, Simpson F. Chew HY, et al. Cell. 2020 Mar 5;180(5):895-914.e27. doi: 10.1016/j.cell.2020.02.019. Cell. 2020. PMID: 32142680 Free article.
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A Azad A, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Siva S, et al. Among authors: cuff ke. Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23. Eur Urol. 2022. PMID: 34953600 Clinical Trial.
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Wong V, et al. Clin Breast Cancer. 2022 Dec;22(8):792-800. doi: 10.1016/j.clbc.2022.08.011. Epub 2022 Aug 30. Clin Breast Cancer. 2022. PMID: 36151018
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Donskov F, et al. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27. Eur J Cancer. 2020. PMID: 31887537 Free PMC article. Clinical Trial.
12 results